fashion -WSS

fashion

author：comprehensive 2025-09-28 02:31:41 - browse：687

Five elderly people have been blinded in one eye by a severe side effect after receiving injections of a newly approved treatment for eye disease from Apellis Pharmaceuticals. The frequency of this side effect — a severe type of eye inflammation — is low but its cause remains unknown.

The new safety information related to the Apellis drug, called Syfovre, was presented Saturday by a committee of eye disease experts at the annual meeting of the American Society of Retinal Specialists (ASRS).

Apellis cooperated with the ASRS analysis but the company also announced its own internal review Saturday that found fewer cases of retinal occlusive vasculitis, a type of severe eye inflammation that blocks blood flow to the retina and can result in blindness. The rate of retinal occlusive vasculitis reported remains “very rare,” the company said, adding that there is no evidence linking the drug product or its manufacturing to the severe side effect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Bernie brings in new pharma CEOs to talk drug prices

hotspot

WSS

A single Democrat is willing to weaken Medicare negotiation power

3 hurdles to bringing medical devices to the U.S. market

Death of patient in Alzheimer’s trial raises question of possible risks

3 hurdles to bringing medical devices to the U.S. market

Gene therapy has helped boys walk. Can scientists keep it that way?

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Wikipedia

fashion

leisure time

At least 13 dead in Texas as scorching temps continue

Surgery pushed Ben Carson to fame

United colonoscopy coverage change 'may cost lives,' doctors say

Weight bias in eating disorder treatment complicated by new weight loss drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Biogen Aduhelm mess could happen again

What does generative AI mean for health care? We asked experts

Death of patient in Alzheimer’s trial raises question of possible risks

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why are elite athletes different? Take a look at their microbes

focus

AstraZeneca stays mum on Medicare drug pricing negotiations

The battle over the Brookhaven Landfill on Long Island

What would happen to your eyes if you looked at the solar eclipse?

Surgery pushed Ben Carson to fame

Donald Trump's relentless attacks on special counsel Jack Smith

Devoted Health’s losses in Medicare Advantage persist

hotspot

focus

Wikipedia

focus